Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NACATRINE: Neoadjuvant Carboplatin in TNBC
NCT02978495Phase 2Completed
- Sponsor
- Hospital de Amor
- Start
- May 2017
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin in triple-negative breast cancer (TNBC) (4 arms), sponsored by Hospital de Amor. Primary endpoint: Pathological Complete Response. Started May 2017; status: completed.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02978495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978495.